IQVIA Holdings Inc. (IQV) Gross Margin: 26.28%
Is IQVIA Holdings Inc.’s gross margin high or low?
IQVIA Holdings Inc.'s gross margin of 26.28% is 21% below its 5-year average of 33.07%, near the low end of its 5-year range (26.28%–34.96%).
The gross margin for IQVIA Holdings Inc. (IQV) is 26.28% as of Tuesday, June 9, 2026. It is below its 12-month average by 14.08% (30.59%).
IQV Gross Margin Chart
IQV Average Gross Margin Chart
IQV Current vs Average Gross Margin Chart
IQV Gross Margin Metrics
GROSS MARGIN
26.28%
GROSS MARGIN AVG TTM
30.59%
GROSS MARGIN AVG 3Y
32.75%
GROSS MARGIN AVG 5Y
33.07%
GROSS MARGIN AVG 10Y
32.86%
GROSS MARGIN AVG 15Y
30.96%
GROSS MARGIN AVG 20Y
30.96%
CURRENT VS TTM AVG
-14.08%
CURRENT VS 3Y AVG
-19.77%
CURRENT VS 5Y AVG
-20.54%
CURRENT VS 10Y AVG
-20.02%
CURRENT VS 15Y AVG
-15.12%
CURRENT VS 20Y AVG
-15.12%
IQV Competitors' Gross Margin
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IQVIA Holdings Inc. (IQV) | — | 26.28% | 30.59% | 32.75% | 33.07% |
| DexCom, Inc. (DXCM) | $30.17B | 60.01% | 60.23% | 62.09% | 63.91% |
| Centene Corporation (CNC) | $32.69B | 12.24% | 11.28% | 11.33% | 11.71% |
| Biogen Inc. (BIIB) | $29.39B | 70.47% | 73.30% | 74.61% | 77.63% |
| Zoetis Inc. (ZTS) | $34.46B | 70.49% | 69.79% | 68.91% | 68.46% |
| Veeva Systems Inc. (VEEV) | $27.37B | 75.53% | 75.03% | 73.28% | 73.00% |
| Waters Corporation (WAT) | $24.19B | 57.77% | 58.60% | 58.69% | 58.45% |
| Agilent Technologies, Inc. (A) | $38.26B | 52.43% | 53.36% | 52.95% | 53.14% |
| Mettler-Toledo International Inc. (MTD) | $23.50B | 57.52% | 57.84% | 57.54% | 57.23% |
| BioNTech SE (BNTX) | $21.87B | 77.64% | 78.98% | 81.24% | 82.89% |
Gross Margin Analysis
Gross Margin
26.3%
(Revenue - COGS) / Revenue
IQVIA Holdings Inc. Gross Margin Formula & Definition
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
IQVIA Holdings Inc. Gross Margin FAQ
- What is the gross margin for IQVIA Holdings Inc. (IQV)?
- The gross margin for IQV stock is 26.28%.
- Is IQVIA Holdings Inc.'s gross margin high or low?
- IQVIA Holdings Inc.'s gross margin of 26.28% is 21% below its 5-year average of 33.07%, near the low end of its 5-year range (26.28%–34.96%).
- What is the TTM average gross margin for IQVIA Holdings Inc. (IQV)?
- The TTM average gross margin for IQV stock is 30.59%.
- What is the 3Y average gross margin for IQVIA Holdings Inc. (IQV)?
- The 3Y average gross margin for IQV stock is 32.75%.
- What is the 5Y average gross margin for IQVIA Holdings Inc. (IQV)?
- The 5Y average gross margin for IQV stock is 33.07%.
- What is the 10Y average gross margin for IQVIA Holdings Inc. (IQV)?
- The 10Y average gross margin for IQV stock is 32.86%.
- What is the 15Y average gross margin for IQVIA Holdings Inc. (IQV)?
- The 15Y average gross margin for IQV stock is 30.96%.
- What is the 20Y average gross margin for IQVIA Holdings Inc. (IQV)?
- The 20Y average gross margin for IQV stock is 30.96%.
IQVIA Holdings Inc. Gross Margin History
| DATE | GROSS MARGIN |
|---|---|
| 2025-12-31 | 26.28% |
| 2024-12-31 | 34.89% |
| 2023-12-31 | 34.96% |
| 2022-12-31 | 34.89% |
| 2021-12-31 | 33.45% |
| 2020-12-31 | 33.97% |
| 2019-12-31 | 34.16% |
| 2018-12-31 | 35.21% |
| 2017-12-31 | 35.05% |
| 2016-12-31 | 30.33% |
| 2015-12-31 | 28.26% |
| 2014-12-31 | 27.49% |
| 2013-12-31 | 26.22% |
| 2012-12-31 | 25.34% |
| 2011-12-31 | 26.39% |
| 2010-12-31 | 28.52% |
Related Metrics
About IQVIA Holdings Inc.
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Ari Bousbib